IF they have to do a full Phase III and everything goes smoothly sometime in 2016. I say if because they could get a break considering the excessive amount of existing data for PRO 140. Obviously we've had some help with the FDA already and their involvement with this phase 2b means they are paying attention now. I'm not a seasoned biotech pro though. I'm sure it will be a interesting ride.
News 
Market Data 
Discover 
